PLoS ONE (Jan 2022)

Investigation of urinary metabolomics in a phase I hookworm vaccine trial in Gabon

  • Madeleine Eunice Betouke Ongwe,
  • Yoanne D. Mouwenda,
  • Koen A. Stam,
  • Peter G. Kremsner,
  • Bertrand Lell,
  • David Diemert,
  • Jeff Bethony,
  • Maria E. Bottazzi,
  • Peter J. Hotez,
  • Remko V. Leeuwen,
  • Martin P. Grobusch,
  • Ayola A. Adegnika,
  • Oleg A. Mayboroda,
  • Maria Yazdanbakhsh

Journal volume & issue
Vol. 17, no. 9

Abstract

Read online

Metabolomics provides a powerful tool to study physiological changes in response to various perturbations such as vaccination. We explored whether metabolomic changes could be seen after vaccination in a phase I trial where Gabonese adults living either in rural or semi-urban areas received the subunit hookworm vaccine candidates (Na-GST-1 and Na-APR-1 (M74) adjuvanted with Alhydrogel plus GLA-AF (n = 24) or the hepatitis B vaccine (n = 8) as control. Urine samples were collected and assayed using targeted 1H NMR spectroscopy. At baseline, a set of metabolites significantly distinguished rural from semi-urban individuals. The pre- and post-vaccination comparisons indicated significant changes in few metabolites but only one day after the first vaccination. There was no relationship with immunogenicity. In conclusion, in a small phase 1 trial, urinary metabolomics could distinguish volunteers with different environmental exposures and reflected the safety of the vaccines but did not show a relationship to immunogenicity.